Drug-induced steatohepatitis

Clinics in Liver Disease

Volumn 17, Issue 4, 2013, Pages 533-546

  Patel, Vaishali ^a   Sanyal, Arun J ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Drug induced steatohepatitis; Microvesicular and macrovesicular steatosis; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; COCAINE; COENZYME A; DIDANOSINE; FLUOROURACIL; GLUCOCORTICOID; IBUPROFEN; IRINOTECAN; METHOTREXATE; NAPROXEN; TAMOXIFEN; TETRACYCLINE; THIOESTER; TROGLITAZONE; VALPROIC ACID; VINYL CHLORIDE; ZIDOVUDINE;

DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG INDUCED DISEASE; DRUG INDUCED STEATOHEPATITIS; FATTY ACID OXIDATION; FATTY LIVER; HUMAN; LIPID STORAGE; LIVER FUNCTION; MACROVESICULAR STEATOSIS; METABOLIC SYNDROME X; MICROVESICULAR STEATOSIS; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; REVIEW; TOXIC HEPATITIS;

DRUG-INDUCED STEATOHEPATITIS; MICROVESICULAR AND MACROVESICULAR STEATOSIS; NONALCOHOLIC FATTY LIVER DISEASE; NONALCOHOLIC STEATOHEPATITIS;

ANIMALS; DRUG-INDUCED LIVER INJURY; FATTY LIVER; HUMANS;

EID: 84884915072     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2013.07.012     Document Type: Review

References (78)

1. Marchesini G., Bugianesi E., Forlani G., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37:917-923.
2. Chalasani N., Younossi Z., Lavine J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55:2005-2023.
3. Dam-Larsen S., Franzmann M., Andersen I.B., et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004, 53:750-755.
4. Matteoni C.A., Younossi Z.M., Gramlich T., et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-1419.
5. Angulo P. Diagnosing steatohepatitis and predicting liver-related mortality in patients with NAFLD: two distinct concepts. Hepatology 2011, 53:1792-1794.
6. Caldwell S.H., Oelsner D.H., Iezzoni J.C., et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999, 29:664-669.
7. Rockey D.C., Seeff L.B., Rochon J., et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 2010, 51:2117-2126.
8. Benichou C., Danan G., Flahault A. Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. JClin Epidemiol 1993, 46:1331-1336.
9. Danan G., Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. JClin Epidemiol 1993, 46:1323-1330.
10. Stravitz R.T., Sanyal A.J. Drug-induced steatohepatitis. Clin Liver Dis 2003, 7:435-451.
11. Farrell G.C. Drugs and steatohepatitis. Semin Liver Dis 2002, 22:185-194.
12. Pessayre D., Fromenty B., Berson A., et al. Central role of mitochondria in drug-induced liver injury. Drug Metab Rev 2012, 44:34-87.
13. Donnelly K.L., Smith C.I., Schwarzenberg S.J., et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. JClin Invest 2005, 115:1343-1351.
14. Fromenty B., Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther 1995, 67:101-154.
15. Watmough N.J., Bindoff L.A., Birch-Machin M.A., et al. Impaired mitochondrial beta-oxidation in a patient with an abnormality of the respiratory chain. Studies in skeletal muscle mitochondria. JClin Invest 1990, 85:177-184.
16. Koek G.H., Liedorp P.R., Bast A. The role of oxidative stress in non-alcoholic steatohepatitis. Clin Chim Acta 2011, 412:1297-1305.
17. Saudubray J.M., Martin D., de Lonlay P., et al. Recognition and management of fatty acid oxidation defects: a series of 107 patients. JInherit Metab Dis 1999, 22:488-502.
18. Fromenty B., Grimbert S., Mansouri A., et al. Hepatic mitochondrial DNA deletion in alcoholics: association with microvesicular steatosis. Gastroenterology 1995, 108:193-200.
19. Kimura S., Kobayashi T., Tanaka Y., et al. Liver histopathology in clinical Reye syndrome. Brain Dev 1991, 13:95-100.
20. Fulgencio J.P., Kohl C., Girard J., et al. Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats. Diabetes 1996, 45:1556-1562.
21. Eadie M.J., Hooper W.D., Dickinson R.G. Valproate-associated hepatotoxicity and its biochemical mechanisms. Med Toxicol Adverse Drug Exp 1988, 3:85-106.
22. Goldman I.S., Winkler M.L., Raper S.E., et al. Increased hepatic density and phospholipidosis due to amiodarone. AJR Am J Roentgenol 1985, 144:541-546.
23. Lenhard J.M., Croom D.K., Weiel J.E., et al. HIV protease inhibitors stimulate hepatic triglyceride synthesis. Arterioscler Thromb Vasc Biol 2000, 20:2625-2629.
24. Letteron P., Brahimi-Bourouina N., Robin M.A., et al. Glucocorticoids inhibit mitochondrial matrix acyl-CoA dehydrogenases and fatty acid beta-oxidation. AmJ Physiol 1997, 272:G1141-G1150.
25. Lauressergues E., Staels B., Valeille K., et al. Antipsychotic drug action on SREBPs-related lipogenesis and cholesterogenesis in primary rat hepatocytes. Naunyn Schmiedebergs Arch Pharmacol 2010, 381:427-439.
26. Cai D., Yuan M., Frantz D.F., et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005, 11:183-190.
27. Deschamps D., Fisch C., Fromenty B., et al. Inhibition by salicylic acid of the activation and thus oxidation of long chain fatty acids. Possible role in the development of Reye's syndrome. JPharmacol Exp Ther 1991, 259:894-904.
28. Oh K.W., Qian T., Brenner D.A., et al. Salicylate enhances necrosis and apoptosis mediated by the mitochondrial permeability transition. Toxicol Sci 2003, 73:44-52.
29. Wanless I.R., Dore S., Gopinath N., et al. Histopathology of cocaine hepatotoxicity. Report of four patients. Gastroenterology 1990, 98:497-501.
30. Roberts S.M., Harbison R.D., James R.C. Human microsomal N-oxidative metabolism of cocaine. Drug Metab Dispos 1991, 19:1046-1051.
31. Shi X., Yao D., Gosnell B.A., et al. Lipidomic profiling reveals protective function of fatty acid oxidation in cocaine-induced hepatotoxicity. JLipid Res 2012, 53:2318-2330.
32. Luef G.J., Waldmann M., Sturm W., et al. Valproate therapy and nonalcoholic fatty liver disease. Ann Neurol 2004, 55:729-732.
33. Brivet F.G., Nion I., Megarbane B., et al. Fatal lactic acidosis and liver steatosis associated with didanosine and stavudine treatment: a respiratory chain dysfunction?. JHepatol 2000, 32:364-365.
34. Chariot P., Drogou I., de Lacroix-Szmania I., et al. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. JHepatol 1999, 30:156-160.
35. Stankov M.V., Panayotova-Dimitrova D., Leverkus M., et al. Autophagy inhibition due to thymidine analogues as novel mechanism leading to hepatocyte dysfunction and lipid accumulation. AIDS 2012, 26:1995-2006.
36. Osler M., Stead D., Rebe K., et al. Risk factors for and clinical characteristics of severe hyperlactataemia in patients receiving antiretroviral therapy: a case-control study. HIV Med 2010, 11:121-129.
37. Neuman M.G., Schneider M., Nanau R.M., et al. HIV-antiretroviral therapy induced liver, gastrointestinal, and pancreatic injury. Int J Hepatol 2012, 2012:760706.
38. Letteron P., Sutton A., Mansouri A., et al. Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology 2003, 38:133-140.
39. Freneaux E., Fromenty B., Berson A., et al. Stereoselective and nonstereoselective effects of ibuprofen enantiomers on mitochondrial beta-oxidation of fatty acids. JPharmacol Exp Ther 1990, 255:529-535.
40. Victorino R.M., Silveira J.C., Baptista A., et al. Jaundice associated with naproxen. Postgrad Med J 1980, 56:368-370.
41. Lewis J.H., Ranard R.C., Caruso A., et al. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology 1989, 9:679-685.
42. Podrid P.J. Amiodarone: reevaluation of an old drug. Ann Intern Med 1995, 122:689-700.
43. Kalantzis N., Gabriel P., Mouzas J., et al. Acute amiodarone-induced hepatitis. Hepatogastroenterology 1991, 38:71-74.
44. Chang C.C., Petrelli M., Tomashefski J.F., et al. Severe intrahepatic cholestasis caused by amiodarone toxicity after withdrawal of the drug: a case report and review of the literature. Arch Pathol Lab Med 1999, 123:251-256.
45. Guigui B., Perrot S., Berry J.P., et al. Amiodarone-induced hepatic phospholipidosis: a morphological alteration independent of pseudoalcoholic liver disease. Hepatology 1988, 8:1063-1068.
46. Lewis J.H., Mullick F., Ishak K.G., et al. Histopathologic analysis of suspected amiodarone hepatotoxicity. Hum Pathol 1990, 21:59-67.
47. Antherieu S., Rogue A., Fromenty B., et al. Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in HepaRG cells. Hepatology 2011, 53:1895-1905.
48. Fromenty B., Fisch C., Labbe G., et al. Amiodarone inhibits the mitochondrial beta-oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. JPharmacol Exp Ther 1990, 255:1371-1376.
49. Kennedy J.A., Unger S.A., Horowitz J.D. Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol 1996, 52:273-280.
50. Fromenty B., Fisch C., Berson A., et al. Dual effect of amiodarone on mitochondrial respiration. Initial protonophoric uncoupling effect followed by inhibition of the respiratory chain at the levels of complex I and complex II. JPharmacol Exp Ther 1990, 255:1377-1384.
51. Pessayre D., Mansouri A., Haouzi D., et al. Hepatotoxicity due to mitochondrial dysfunction. Cell Biol Toxicol 1999, 15:367-373.
52. Pessayre D., Bichara M., Degott C., et al. Perhexiline maleate-induced cirrhosis. Gastroenterology 1979, 76:170-177.
53. Kubo M., Hostetler K.Y. Metabolic basis of diethylaminoethoxyhexestrol-induced phospholipid fatty liver. Am J Physiol 1987, 252:E375-E379.
54. Le Gall J.Y., Guillouzo A., Glaise D., et al. Perhexiline maleate toxicity on human liver cell lines. Gut 1980, 21:977-984.
55. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355:1041-1047.
56. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. JClin Oncol 2004, 22:229-237.
57. Levi F., Zidani R., Misset J.L. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 1997, 350:681-686.
58. Adam R., Delvart V., Pascal G., et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004, 240:644-657. [discussion: 657-8].
59. Bismuth H., Adam R., Levi F., et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996, 224:509-520. [discussion: 520-2].
60. Gentilucci U.V., Santini D., Vincenzi B., et al. Chemotherapy-induced steatohepatitis in colorectal cancer patients. JClin Oncol 2006, 24:5467. [author reply: 5467-8].
61. Rubbia-Brandt L., Audard V., Sartoretti P., et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004, 15:460-466.
62. Brouquet A., Benoist S., Julie C., et al. Risk factors for chemotherapy-associated liver injuries: a multivariate analysis of a group of 146 patients with colorectal metastases. Surgery 2009, 145:362-371.
63. Schwarz R.E., Berlin J.D., Lenz H.J., et al. Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement. HPB (Oxford) 2013, 15:106-115.
64. Cho J.Y., Suh K.S., Kwon C.H., et al. Mild hepatic steatosis is not a major risk factor for hepatectomy and regenerative power is not impaired. Surgery 2006, 139:508-515.
65. Kooby D.A., Fong Y., Suriawinata A., et al. Impact of steatosis on perioperative outcome following hepatic resection. JGastrointest Surg 2003, 7:1034-1044.
66. Menter A., Korman N.J., Elmets C.A., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. JAm Acad Dermatol 2009, 61:451-485.
67. Langman G., Hall P.M., Todd G. Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. JGastroenterol Hepatol 2001, 16:1395-1401.
68. Berends M.A., van Oijen M.G., Snoek J., et al. Reliability of the Roenigk classification of liver damage after methotrexate treatment for psoriasis: a clinicopathologic study of 160 liver biopsy specimens. Arch Dermatol 2007, 143:1515-1519.
69. Hytiroglou P., Tobias H., Saxena R., et al. The canals of Hering might represent a target of methotrexate hepatic toxicity. Am J Clin Pathol 2004, 121:324-329.
70. Yamamoto N., Oliveira M.B., Campello Ade P., et al. Methotrexate: studies on the cellular metabolism. I. Effect on mitochondrial oxygen uptake and oxidative phosphorylation. Cell Biochem Funct 1988, 6:61-66.
71. Ogawa Y., Murata Y., Nishioka A., et al. Tamoxifen-induced fatty liver in patients with breast cancer. Lancet 1998, 351:725.
72. Pratt D.S., Knox T.A., Erban J. Tamoxifen-induced steatohepatitis. Ann Intern Med 1995, 123:236.
73. Murata Y., Ogawa Y., Saibara T., et al. Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients. Oncol Rep 2000, 7:1299-1304.
74. Bruno S., Maisonneuve P., Castellana P., et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 2005, 330:932.
75. Nishino M., Hayakawa K., Nakamura Y., et al. Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy. AJR Am J Roentgenol 2003, 180:129-134.
76. Saphner T., Triest-Robertson S., Li H., et al. The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer. Cancer 2009, 115:3189-3195.
77. Cole L.K., Jacobs R.L., Vance D.E. Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis. Hepatology 2010, 52:1258-1265.
78. Letteron P., Fromenty B., Terris B., et al. Acute and chronic hepatic steatosis lead to invivo lipid peroxidation in mice. JHepatol 1996, 24:200-208.